Odonate Therapeutics, Inc. Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2021-09-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2021-09-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2021-09-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2021-09-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2021-09-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 82.50M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 6.49M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -102.32M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2021-09-30 | $82.50M | (m) | $6.49M | $-102.32M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $107.87M | (m) | $8.09M | $-118.96M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $120.02M | (m) | $9.34M | $-130.43M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $117.04M | (m) | $9.83M | $-127.43M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $112.82M | (m) | $10.27M | $-123.71M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $109.67M | (m) | $10.71M | $-120.82M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $105.35M | (m) | $11.11M | $-116.53M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $104.03M | (m) | $11.44M | $-114.93M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $104.98M | (m) | $10.64M | $-115.70M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $101.55M | (m) | $10.04M | $-112.56M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $92.12M | (m) | $8.63M | $-103.11M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $79.95M | (m) | $6.72M | $-90.76M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $66.19M | (m) | $5.76M | $-77.03M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $53.65M | (m) | $5.47M | $-62.78M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $39.91M | (m) | $4.19M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $27.90M | (m) | $3.18M | $-32.74M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.